We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

BONVIVA(Ibandronate) PMS(Post-marketing Surveillance ) (BONPMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01381393
Recruitment Status : Completed
First Posted : June 27, 2011
Last Update Posted : November 30, 2012
Information provided by (Responsible Party):

Brief Summary:
This is an open label, multi-centre, non-interventional post-marketing surveillance.

Condition or disease Intervention/treatment
Osteoporosis Drug: Ibandronate

Detailed Description:
This is an open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of ibandronate administered in Korean patients according to the prescribing information.

Study Type : Observational
Actual Enrollment : 659 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety of BONVIVA(Ibandronate) Administered in Korean Patients According to the Prescribing Information
Study Start Date : June 2007
Primary Completion Date : March 2012
Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis
U.S. FDA Resources

Group/Cohort Intervention/treatment
The subjects with osteoporosis in postmenopausal women
Drug: Ibandronate
Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Other Name: BONVIVA

Primary Outcome Measures :
  1. The number of adverse event after ibandronate administration [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. The number of unexpected adverse events after ibandronate administration [ Time Frame: 6 months ]
  2. The number of serious adverse events after ibandronate administration [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients administrated ibandronate with postmenopausal osteoporosis in Korea

Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

  1. Subjects diagnosed with osteoporosis in postmenopausal women.
  2. Subjects who the investigator believes that they can and will comply with the requirements of the protocol
  3. Subjects with no experience of treatment using ibandronate.
  4. Subjects who are administered of ibandronate in normal prescription use

Exclusion Criteria:

Considering the nature of this non-interventional PMS study, there is no strict exclusion criteria set up. The doctors participating this study to enrol the subjects prescribed with ibandronate following the locally approved Prescribing Information.

The following criteria should be checked at the time of study entry.

According to contraindication on the prescribing information, ibandronate should not be administered to the following patients:

  1. Patients with known hypersensitivity to ibandronate or to any of its excipients
  2. Uncorrected hypocalcemia
  3. Inability to stand or sit upright for at least 60 minutes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01381393

Korea, Republic of
GSK Investigational Site
Seoul, Korea, Republic of, 137-701
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01381393     History of Changes
Other Study ID Numbers: 110603
First Posted: June 27, 2011    Key Record Dates
Last Update Posted: November 30, 2012
Last Verified: November 2012

Keywords provided by GlaxoSmithKline:

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Ibandronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs